Publications

Detailed Information

Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B

DC Field Value Language
dc.contributor.authorLee, Jeong-Hoon-
dc.contributor.authorYoon, Jung-Hwan-
dc.contributor.authorCho, Eun Ju-
dc.contributor.authorYang, Hyo Joon-
dc.contributor.authorJang, Eun Sun-
dc.contributor.authorKwak, Min-Sun-
dc.contributor.authorHwang, Sang Youn-
dc.contributor.authorYu, Su Jong-
dc.contributor.authorLee, Chang-Hoon-
dc.contributor.authorKim, Yoon Jun-
dc.contributor.authorKim, Chung Yong-
dc.contributor.authorLee, Hyo-Suk-
dc.date.accessioned2023-12-11T07:45:58Z-
dc.date.available2023-12-11T07:45:58Z-
dc.date.created2020-08-27-
dc.date.issued2012-03-
dc.identifier.citationJournal of Clinical Gastroenterology, Vol.46 No.3, pp.243-250-
dc.identifier.issn0192-0790-
dc.identifier.urihttps://hdl.handle.net/10371/198645-
dc.description.abstractGoal: In this study, we aimed to devise a simple scoring system predicting the risk of genotypic resistance (GR) to current rescue therapies for patients with lamivudine (LAM)-resistant chronic hepatitis B. Background: LAM and adefovir (ADV) combination therapy should be recommended for an initial rescue therapy against LAM-resistant hepatitis B virus (HBV). However, there still are many LAM-resistant patients being treated with entecavir (ETV) or ADV monotherapy. Study: This retrospective cohort study included consecutive patients treated for LAM-resistant chronic hepatitis B with ETV or ADV monotherapy, or LAM/ADV combination therapy. The cumulative probabilities of GR and virological responses and breakthrough according to clinical variables were analyzed by survival analyses and derived an index for future GR. Results: A total of 224 patients were included (median treatment duration = 117.9 wk). Using risk factors indentified on multivariable analyses, a simple index for future GR (Antiviral Resistance Prediction Index, ARPI) was developed with 3 clinical variables: the rescue therapy regimens (+0, ADV; +1, ETV; +2, LAM/ADV), HBV DNA reduction at 12 weeks (+0, < 3 log(10) copies/mL; +1, >3 log(10) copies/mL), and the initial HBV DNA level (+0, > 10(6) copies/mL; +1, < 10(6) copies/mL). No patient with ARPI >= 2 exhibited GR, whereas 47% of the patients with an ARPI < 2 developed GR by week 144 (P = 0.005). Conclusions: The results of this study suggest that the ARPI is a simple and early index that can be used to determine the risk for subsequent GR during rescue therapy for LAM-resistant chronic hepatitis B.-
dc.language영어-
dc.publisherLippincott Williams & Wilkins Ltd.-
dc.titleSimple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B-
dc.typeArticle-
dc.identifier.doi10.1097/MCG.0b013e318225f559-
dc.citation.journaltitleJournal of Clinical Gastroenterology-
dc.identifier.wosid000300518700012-
dc.identifier.scopusid2-s2.0-84857048627-
dc.citation.endpage250-
dc.citation.number3-
dc.citation.startpage243-
dc.citation.volume46-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorYoon, Jung-Hwan-
dc.contributor.affiliatedAuthorKim, Yoon Jun-
dc.contributor.affiliatedAuthorLee, Hyo-Suk-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusCOMBINATION THERAPY-
dc.subject.keywordPlusADEFOVIR DIPIVOXIL-
dc.subject.keywordPlusENTECAVIR-
dc.subject.keywordPlusMONOTHERAPY-
dc.subject.keywordPlusMANAGEMENT-
dc.subject.keywordPlusEFFICACY-
dc.subject.keywordPlusUPDATE-
dc.subject.keywordPlusHBV-
dc.subject.keywordAuthorchronic hepatitis B-
dc.subject.keywordAuthorgenotypic resistance-
dc.subject.keywordAuthorrescue therapy-
dc.subject.keywordAuthorAntiviral Resistance Prediction Index-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share